{"pmid":32314704,"title":"Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency.","text":["Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency.","Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency.","Am J Trop Med Hyg","Chaccour, Carlos","Hammann, Felix","Ramon-Garcia, Santiago","Rabinovich, N Regina","32314704"],"abstract":["Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency."],"journal":"Am J Trop Med Hyg","authors":["Chaccour, Carlos","Hammann, Felix","Ramon-Garcia, Santiago","Rabinovich, N Regina"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314704","week":"202017|Apr 20 - Apr 26","doi":"10.4269/ajtmh.20-0271","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664714519988928512,"score":8.518259,"similar":[{"pmid":32322397,"pmcid":"PMC7175902","title":"Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.","text":["Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.","Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection.","New Microbes New Infect","Choudhary, Renuka","Sharma, Anil K","Choudhary, Renuka","32322397"],"abstract":["Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection."],"journal":"New Microbes New Infect","authors":["Choudhary, Renuka","Sharma, Anil K","Choudhary, Renuka"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32322397","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.nmni.2020.100684","keywords":["azithromycin","coronavirus","hydroxychloroquine","ivermectin"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Ivermectin","Hydroxychloroquine","Azithromycin"],"_version_":1664895932681945088,"score":145.58186},{"pmid":32251768,"title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.","text":["The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.","Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.","Antiviral Res","Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M","32251768"],"abstract":["Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."],"journal":"Antiviral Res","authors":["Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251768","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104787","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136233123840,"score":121.69832},{"pmid":32297590,"title":"Rigorous Randomized Controlled Trial Implementation in the Era of Novel Coronavirus Disease (COVID-19).","text":["Rigorous Randomized Controlled Trial Implementation in the Era of Novel Coronavirus Disease (COVID-19).","Rigorous Randomized Controlled Trial Implementation in the Era of Novel Coronavirus Disease (COVID-19).","Am J Trop Med Hyg","Oldenburg, Catherine E","Doan, Thuy","32297590"],"abstract":["Rigorous Randomized Controlled Trial Implementation in the Era of Novel Coronavirus Disease (COVID-19)."],"journal":"Am J Trop Med Hyg","authors":["Oldenburg, Catherine E","Doan, Thuy"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297590","week":"202016|Apr 13 - Apr 19","doi":"10.4269/ajtmh.20-0262","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664641388241747968,"score":111.50239},{"pmid":32219627,"title":"Development Path and Urgency of further Strengthening Construction of Public Hospitals Based on Novel Coronavirus Pneumonia Treatment.","text":["Development Path and Urgency of further Strengthening Construction of Public Hospitals Based on Novel Coronavirus Pneumonia Treatment.","During the outbreak of novel coronavirus pneumonia (NCP) in Wuhan, public hospitals have played an important role in intensive care, case guidance and scheme optimization. At the same time, it also faces unprecedented challenges and tests. Based on the treatment of severe patients in Wuhan, combined with the treatment practice in Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, this paper puts forward the urgency of further strengthening the construction of public hospitals, discusses the feasible path for promoting the development of public hospitals, so as to meet the growing medical needs of the people, improve the ability to respond to major public health emergencies, and effectively guarantee the safety of people's lives and the promotion of a healthy China construction.","Curr Med Sci","Liao, Jia-Zhi","Wu, Jing","32219627"],"abstract":["During the outbreak of novel coronavirus pneumonia (NCP) in Wuhan, public hospitals have played an important role in intensive care, case guidance and scheme optimization. At the same time, it also faces unprecedented challenges and tests. Based on the treatment of severe patients in Wuhan, combined with the treatment practice in Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, this paper puts forward the urgency of further strengthening the construction of public hospitals, discusses the feasible path for promoting the development of public hospitals, so as to meet the growing medical needs of the people, improve the ability to respond to major public health emergencies, and effectively guarantee the safety of people's lives and the promotion of a healthy China construction."],"journal":"Curr Med Sci","authors":["Liao, Jia-Zhi","Wu, Jing"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219627","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s11596-020-2175-3","keywords":["construction","epidemic prevention and control","novel coronavirus pneumonia","public health emergency","public hospital"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Wuhan","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638743013752832,"score":83.42387},{"pmid":32296817,"title":"Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials.","text":["Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials.","Investigators are employing unprecedented innovation in the design of clinical trials to rapidly and rigorously assess potentially promising therapies for COVID-19; this is in stark contrast to the continued near universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials which allow their inclusion focus on post-exposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies. These restrictions were put in place despite experience with these drugs in pregnant women. In this Viewpoint, we call attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order to develop data-driven recommendations regarding the risks and benefits of therapies in this unique but not uncommon population.","Clin Infect Dis","LaCourse, Sylvia M","John-Stewart, Grace","Adams Waldorf, Kristina M","32296817"],"abstract":["Investigators are employing unprecedented innovation in the design of clinical trials to rapidly and rigorously assess potentially promising therapies for COVID-19; this is in stark contrast to the continued near universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials which allow their inclusion focus on post-exposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies. These restrictions were put in place despite experience with these drugs in pregnant women. In this Viewpoint, we call attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order to develop data-driven recommendations regarding the risks and benefits of therapies in this unique but not uncommon population."],"journal":"Clin Infect Dis","authors":["LaCourse, Sylvia M","John-Stewart, Grace","Adams Waldorf, Kristina M"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296817","week":"202016|Apr 13 - Apr 19","doi":"10.1093/cid/ciaa444","keywords":["covid-19","pregnancy","treatment","trial"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Hydroxychloroquine","remdesivir"],"_version_":1664641388393791488,"score":65.1087}]}